Vnitr Lek 2006, 52(12):1185-1189

Non-arrhythmic therapy of ventricular tachyarrhythmias and sudden cardiac death after acute myocardial infarction

P. Schweitzer
Division of Cardiology, Department of Medicine, Beth Israel Medical Center and Albert Einstein College of Medicine, New York, USA

The management of ventricular tachyarrhythmias and prevention of sudden cardiac death after acute myocardial infarction (AMI) underwent important evolution. In the CAST study, encanaide and other antiarrhythmic drugs were not only ineffective but also increased mortality after myocardial infarction. Amiodarone had some beneficial effect on arrhythmic events without improving survival, and ICDs failed to improve outcome early after AMI. In comparison, short and long term survival benefits of beta blockers, angiotensine converting enzyme inhibitors and aldosterone antagonists after AMI is well established. This review discusses the role of non-arrhythmic therapy in the prevention of ventricular tachyarrhythmia's and sudden cardiac death after AMI.

Keywords: ventricular tachyarrhythmias; sudden cardiac death; acute myocardial infarction

Received: August 15, 2006; Published: December 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Schweitzer P. Non-arrhythmic therapy of ventricular tachyarrhythmias and sudden cardiac death after acute myocardial infarction. Vnitr Lek. 2006;52(12):1185-1189.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. The cardiac Arrhythmias Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-412. Go to original source... Go to PubMed...
    2. Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667-674.
    3. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarization: CAMIAT. Lancet 1997; 349: 675-682.
    4. Moss AJ, Hall WJ, Cannon DS et al. Improved Survival with an implantable defibrillator in patients with coronary artery disease at high risk for ventricular arrhythmias. N Engl J Med 1996; 335: 1933-1940. Go to original source... Go to PubMed...
    5. Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883. Go to original source... Go to PubMed...
    6. Hohnloser SH, Kuck KH, Dorian P et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351: 2481-2488. Go to original source... Go to PubMed...
    7. Solomon SD, Zelenkofske S, McMurray JJV et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure or both. N Engl J Med 2005; 352: 2581-2588. Go to original source... Go to PubMed...
    8. Holmes DR Jr, Davis KB, Mock MB et al. The effect of medical and surgical treatment on subsequent sudden cardiac death in patients with coronary artery disease: a report from the coronary artery surgery study. Circulation 1986; 73: 1254-1263. Go to original source... Go to PubMed...
    9. Bigger JT for the coronary artery bypass graft (CABG) patch trial investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery. N Engl J Med 1997; 337: 1569-1575.
    10. Makikallio TH, Barthel P, Schneider R et al. Frequency of sudden cardiac death among acute myocardial survivors with optimized medical and revascularization therapy. Am J Cardiol 2006; 97: 480-484. Go to original source... Go to PubMed...
    11. Olsson G, Wikstrand J, Warnold I et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J 1992; 13: 28-32. Go to original source... Go to PubMed...
    12. Hjalmarson A. Effect of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. Am J Cardiol 1997; 80: 35J-39J. Go to original source... Go to PubMed...
    13. COMMIT (Clopidrol and Metoprolol in myocardial infarction trial) collaborative group. Early intravenous then oral metoprolol in 45852 patients with acute myocardial infarction randomized placebo-controlled trial. Lancet 2005; 366; 1622-1632. Go to original source... Go to PubMed...
    14. The CAPRICORN Investigators. Effects of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001; 357: 1385-1390. Go to original source... Go to PubMed...
    15. Domanski MJ, Exner DV, Borkowf CB et al. Effect of angiotensine converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999; 33: 598-604. Go to original source... Go to PubMed...
    16. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321. Go to original source... Go to PubMed...
    17. Abildstrom AZ, Rask-Madsen C, Ottsen MM et al on behalf of the TRACE study group. Impact of age and sex on sudden cardiovascular death following myocardial infarction. Heart 2002; 88: 573-578. Go to original source... Go to PubMed...
    18. Wu AH, Parsons L, Every NR et al. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction. J Am Coll Cardiol 2002; 40: 1389-1394. Go to original source... Go to PubMed...
    19. Steg PG, Dabbous OH, Feldman LJ et al. Determinants and prognostic impact of heart failure complicating acute coronary syndrome; Observation from the global registry of acute coronary events (GRACE). Circulation 2004; 109: 494-499. Go to original source... Go to PubMed...
    20. Yap YG, Duong T, Bland M et al. Temporal trend on the risk of arrhythmic vs. nonarhhytmic high-risk patients after myocardial infarction: a combined analysis of multicenter trial. Eur Heart J 2005; 26: 1385-1393. Go to original source... Go to PubMed...
    21. Chadda K, Goldstein S, Byington R et al. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986; 73: 503-510. Go to original source... Go to PubMed...
    22. McMurray J, Kober L, Robertson M et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction; Results of the carvedilol post-infarct survival control in left ventricular dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005; 45: 525-530. Go to original source... Go to PubMed...
    23. Gottlieb SS, Carter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low risk patients after myocardial infarction. N Engl J Med 1998; 339: 489-497. Go to original source... Go to PubMed...
    24. Spargias KS, Hall AS, Greenwood DC et al. Beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study. Heart 1999; 81: 25-32. Go to original source... Go to PubMed...
    25. Ellis K, Tcheng JE, Sapp S et al. Mortality benefit of beta blockade in patients with acute coronary syndrome undergoing coronary intervention: Pooled results from epic, epilog, capture and rapport trial. J Interven Cardiol 2003; 16: 299-305. Go to original source... Go to PubMed...
    26. Kernis SJ, Harjai KJ, Stone GW et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol 2004; 43: 1773-1779. Go to original source... Go to PubMed...
    27. Ellison KE, Hafley GE, Hickey K et al. Effect of beta-blocking therapy on outcome in the multicenter unsustained tachycardia trial (MUSTT). Circulation 2002; 106: 2694-2699. Go to original source... Go to PubMed...
    28. Brodine WN, Tung RT, Lee JK et al. Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in patients with ischemic cardiomyopathy (from the multicenter automatic defibrillator implantation trial-II). Am J Cardiol 2005; 96: 691-695. Go to original source... Go to PubMed...
    29. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-677. Go to original source... Go to PubMed...
    30. Kober L, Torp-Pedersen C, Carlsen JA et al. A clinical trial of the angiotensine-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-1676. Go to original source... Go to PubMed...
    31. The acute infarction ramipril efficacy (AIRE) study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
    32. Ambrosioni E, Borghi C, Magnani B for the survival myocardial infarction long-term evaluation (SMILE) study investigators. N Engl J Med 1995; 332: 80-85. Go to original source... Go to PubMed...
    33. Swedberg K, Held P, Kjekshus J et al. On behalf of the CONSENSUS II study group. N Engl J Med 1992; 327: 678-684. Go to original source... Go to PubMed...
    34. Cleland JGF, Erhardt L, Murray G et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure: A report from the AIRE study investigators. Eur Heart J 1997; 18: 41-51. Go to original source... Go to PubMed...
    35. Dickstein K, Kjekshus J and the OPTIMAL Steering Committee. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAL randomized trial. Lancet 220; 360: 752-760.
    36. Pfeffer MA, McMurray JJ, Veleazguez EJ et al. Valsartan in acute myocardial infarction trial investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906. Go to original source... Go to PubMed...
    37. John JN, Colucci W. Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. Am J Cardiol 2006; 97(Suppl): 4F-12F. Go to original source... Go to PubMed...
    38. Pitt B, White H, Nicolau J et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005; 46: 425-431. Go to original source... Go to PubMed...
    39. Perrier E, Kerfant BG, Lalevec N et al. Mineralcorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation 2004; 110: 776-783. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.